Story

J.P. Morgan Lifts Novo Nordisk Price Target on Strong Ozempic, Wegovy Sales

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20262 min read
J.P. Morgan Lifts Novo Nordisk Price Target on Strong Ozempic, Wegovy Sales
Text size
Background

J.P. Morgan has increased its December 2027 price target for Novo Nordisk (NVO) to 275 Danish crowns from a previous 250 crowns, attributing the revision to stronger sales forecasts for its blockbuster diabetes and weight-loss drugs. In a note published Tuesday, the bank maintained its “neutral” rating on the pharmaceutical giant's stock.

Revised Forecasts

The analyst's optimism is rooted in Novo Nordisk's second-quarter 2026 financial results. J.P. Morgan raised its 2026 sales forecast for the company by 5%, citing several key factors:

  • Ozempic: The forecast for Ozempic sales in 2026 was increased by 8% to 113 billion crowns. This is due to slower-than-expected generic competition and favorable U.S. gross-to-net price adjustments.
  • Wegovy: The forecast for the injectable weight-loss drug was lifted by 7% to 82 billion crowns, driven by robust growth in markets outside the United States.

Looking further ahead, J.P. Morgan increased its 2027-2030 sales forecasts by 6-7% and its adjusted earnings per share (EPS) estimates for 2026-2030 by 4-8%.

A Muted Growth Outlook

Sample IUX Markets – In-articleAd

Despite the upward revisions for its key products, the bank projects a relatively flat top-line for Novo Nordisk in 2026 at constant exchange rates, followed by modest growth of approximately 1% in 2027 and 2% in 2028.

This tempered outlook is partially due to a downward revision for Oral Wegovy, with its 2026 forecast cut by 11% to 18 billion crowns on signs of slowing launch momentum in the U.S. Furthermore, J.P. Morgan expects growth in 2027 to be offset by a decline in Ozempic sales, which will face pressure from volume loss and anticipated price cuts under the U.S. Inflation Reduction Act.

Valuation Basis

The new price target of 275 DKK is based on a valuation of 12 times the bank's estimated 2027 adjusted EPS. According to the note, this multiple represents a roughly 20% discount to the broader pharmaceutical sector. Future growth acceleration beyond 2028 is seen as highly dependent on the company's pipeline, particularly the development of its next-generation oral drug, zenagamtide.

Read next

More on Stocks
Back to latest news

LATEST